VIA
TEVA icon

Vident Investment Advisory’s Teva Pharmaceuticals TEVA Stock Holding History

Vident Investment Advisory’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-22,246
Closed -$168K – 948
2023
Q2 		$168K Buy
22,246
+295
+1% +$2.39K 0.01% 1086
2023
Q1 		$194K Buy
21,951
+2,655
+14% +$26.3K 0.01% 1111
2022
Q4 		$176K Buy
19,296
+7,270
+60% +$63.4K 0.01% 1053
2022
Q3 		$0 Buy
+12,026
New +$106K ﹤0.01% 1315
2016
Q2 		– Sell
-12,734
Closed -$682 – 392
2016
Q1 		$682 Buy
12,734
+9,121
+252% +$535K 0.04% 363
2015
Q4 		$237K Buy
+3,613
New +$223K 0.03% 357

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vident Investment Advisory's TEVA Position: Q3 2023 in Review

Vident Investment Advisory sold out of Teva Pharmaceuticals (TEVA) in Q3 2023, closing a stake of 22,246 shares — an estimated $168K sold.

Vident Investment Advisory first reported a position in TEVA in Q4 2015 and held it in 6 quarters. The position peaked at $237K in Q4 2015. 435 funds tracked by Wall St. Rank hold TEVA as of Q3 2023.

  • Vident Investment Advisory reported no remaining Teva Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Vident Investment Advisory sold 22,246 Teva Pharmaceuticals shares in Q3 2023, an estimated $168K.
  • Vident Investment Advisory first reported a position in Teva Pharmaceuticals in Q4 2015 and held it in 6 quarters.
  • Vident Investment Advisory's Teva Pharmaceuticals position peaked at $237K in Q4 2015.
  • 435 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2023.

Based on Vident Investment Advisory's 13F filing for Q3 2023.